Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Apellis Pharmaceuticals (APLS) Change in Receivables: 2021-2025

Historic Change in Receivables for Apellis Pharmaceuticals (APLS) over the last 4 years, with Sep 2025 value amounting to $131.4 million.

  • Apellis Pharmaceuticals' Change in Receivables rose 616.91% to $131.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $66.5 million, marking a year-over-year decrease of 39.39%. This contributed to the annual value of $58.5 million for FY2024, which is 70.57% down from last year.
  • Latest data reveals that Apellis Pharmaceuticals reported Change in Receivables of $131.4 million as of Q3 2025, which was up 722.23% from -$21.1 million recorded in Q2 2025.
  • Apellis Pharmaceuticals' 5-year Change in Receivables high stood at $131.4 million for Q3 2025, and its period low was -$29.7 million during Q1 2025.
  • For the 3-year period, Apellis Pharmaceuticals' Change in Receivables averaged around $30.7 million, with its median value being $36.6 million (2024).
  • Per our database at Business Quant, Apellis Pharmaceuticals' Change in Receivables soared by 10,284.38% in 2023 and then tumbled by 157.74% in 2025.
  • Over the past 5 years, Apellis Pharmaceuticals' Change in Receivables (Quarterly) stood at $7.5 million in 2021, then tumbled by 104.88% to -$365,000 in 2022, then skyrocketed by 10,284.38% to $37.2 million in 2023, then slumped by 137.89% to -$14.1 million in 2024, then skyrocketed by 616.91% to $131.4 million in 2025.
  • Its Change in Receivables was $131.4 million in Q3 2025, compared to -$21.1 million in Q2 2025 and -$29.7 million in Q1 2025.